| P9072 | derived from organism type | Homo sapiens | Q15978631 |
| P1343 | described by source | The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 |
| | Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. | Q31034362 |
| | A cystic fibrosis pancreatic adenocarcinoma cell line | Q33598519 |
| | Phenotype and genotype of pancreatic cancer cell lines | Q33814471 |
| | Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays | Q33882864 |
| | Essential gene profiles in breast, pancreatic, and ovarian cancer cells. | Q34268870 |
| | Genome-wide analysis of pancreatic cancer using microarray-based techniques | Q34902717 |
| | Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies | Q35609041 |
| | Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas | Q35745306 |
| | Established cell lines used in cystic fibrosis research | Q35908460 |
| | Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors | Q35961180 |
| | TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression | Q36301828 |
| | A landscape of pharmacogenomic interactions in cancer. | Q37140236 |
| | A comprehensive transcriptional portrait of human cancer cell lines | Q37854720 |
| | Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping | Q38494511 |
| | Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling | Q38766765 |
| | A resource for cell line authentication, annotation and quality control | Q38886793 |
| | Signatures of mutation and selection in the cancer genome | Q39737975 |
| | Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization. | Q39996404 |
| | Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays | Q40243352 |
| | Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity | Q40515725 |
| | Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines | Q40559191 |
| | A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene | Q40640693 |
| | KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition | Q42062700 |
| | Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications | Q42801596 |
| | Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. | Q52826734 |
| | Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas | Q78008579 |
| | Next-generation characterization of the Cancer Cell Line Encyclopedia | Q91865441 |
| | An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines | Q92510255 |
| | Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Q92607988 |
| | Distribution of Characteristic Mutations in Native Ductal Adenocarcinoma of the Pancreas and Pancreatic Cancer Cell Lines | Q107100960 |
| P5166 | established from medical condition | cystic fibrosis | Q178194 |
| | pancreatic ductal adenocarcinoma | Q18555956 |